Experience of using montiget in patients with bronchial asthma of moderate to severe course

Zufarov P.S., Saidova Sh.A., Akbarova D.S., Musaeva L.J, Pulatova D.B., Abdumajidova N.H

dc.contributor.author	Zufarov P.S., Saidova Sh.A., Akbarova D.S., Musaeva L.J, Pulatova D.B., Abdumajidova N.H
dc.date.accessioned	2022-10-07T06:10:29Z
dc.date.available	2022-10-07T06:10:29Z
dc.date.issued	2022
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/2513
dc.description.abstract	50 patients aged from 35 to 67 years inclusive with the diagnosis of BA were included in the study. The patients were divided into 2 groups by random sampling. Patients of the first group (control group) -25 people received basic therapy with inhaled glucocorticosteroids and long-acting p2-agonists in the form of combined preparation of Seretide 25/250 meg or 25/500 meg 2 times daily. Patients of the second group -25 people received 25/250 or 50/250 meg Seretide twice a day, and also leukotriene receptor inhibitor Montiget in a dose of 10 mg once daily	en_US
dc.language.iso	en	en_US
dc.publisher	Toshkent	en_US
dc.subject	Experience of using montiget, moderate to severe course	en_US
dc.title	Experience of using montiget in patients with bronchial asthma of moderate to severe course	en_US
dc.type	Thesis	en_US